Sign In
Buy DCTH
$10.33
-0.200 (-1.90%)
At Close: Jun 03, 2026
Delcath Systems Reports Second Quarter 2024 Results and Business Highlights
04:01pm, Monday, 05'th Aug 2024
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic canc
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
01:01pm, Monday, 15'th Jul 2024
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Have $5-10? 7 Affordable Stocks That Are About to Breakout.
06:00am, Thursday, 13'th Jun 2024
Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower.
Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect?
10:56am, Monday, 03'rd Jun 2024
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 197.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors
09:30am, Tuesday, 28'th May 2024
NEW YORK--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t
Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know
10:56am, Friday, 17'th May 2024
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 201.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing'
09:50am, Wednesday, 15'th May 2024
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it thro
Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript
02:16pm, Tuesday, 14'th May 2024
Delcath Systems Inc (NASDAQ:DCTH ) Q1 2024 Results Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Offic
Delcath Systems Reports First Quarter 2024 Results and Business Highlights
07:30am, Tuesday, 14'th May 2024
Conference Call Today at 8:30 am Eastern Time QUEENSBURY, N.Y. , May 14, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focu
Delcath Systems to Host First Quarter 2024 Earnings Call
08:30am, Tuesday, 07'th May 2024
QUEENSBURY, N.Y. , May 7, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announ
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
09:00am, Monday, 06'th May 2024
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%) Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate NEW
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Friday, 03'rd May 2024
NEW YORK , May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
10:56am, Tuesday, 23'rd Apr 2024
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 244.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
10:56am, Friday, 05'th Apr 2024
The consensus price target hints at a 277.7% upside potential for Delcath Systems (DCTH). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:35am, Thursday, 04'th Apr 2024
NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancer
